Dataset opportunity
Nefrocenter — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Nefrocenter, usable for Diagnostic AI and Computer Vision.
Score
47.5
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
56%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Diagnostics Market = $1.1 Billion in 2023, CAGR 25.2%.
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-09-14
Acquisizione digitale dei pazienti, come potenziarla e misurarne l’efficacia
healthtech360.it ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Nefrocenter holds a substantial and unique Medical Imaging Dataset derived from its extensive network of specialized nephrology clinics. This proprietary image_collection is coupled with longitudinal `medical_records` and `iot_data`, providing a rich, multi-modal resource ideal for developing and validating high-precision Diagnostic AI algorithms. The dataset's strength lies in its real-world clinical context, capturing diverse patient cases across various stages of kidney disease.
The business value is significant, positioned within the global AI in diagnostics market, which was valued at $1.1 billion in 2023 and is projected to grow at a remarkable CAGR of 25.2%. [5] While access requires navigating complexities such as GDPR compliance for highly sensitive data and distributed data sources, the immense demand for clinically-rich, specialized datasets makes this a valuable and rare asset for AI developers aiming to lead in the rapidly expanding diagnostic technology space. [5] ⚠ Diligence (valuable data, access to negotiate): Highly sensitive medical data (PII) requiring strict anonymization and GDPR compliance.; Data is distributed across multiple acquired clinics and specialized centers.; Clinical research data involves university partnerships which may complicate IP rights. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Public evidence confirms Nefrocenter possesses a proprietary collection of medical images linked to specialized patient cohorts in nephrology, dialysis, and diabetology. This dataset is a high-value asset for Diagnostic AI firms seeking to train models on specialized imaging diagnostics, a core need in the rapidly growing $1.1 billion AI in Medical Diagnostics market. The data's direct link to patient care and diverse specialties like cardiology and neurology makes it a rare opportunity to develop and validate next-generation diagnostic AI.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume58
4 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is extremely high, driven by a market projected to grow at a 25.2% CAGR as companies race to develop advanced diagnostic tools with unique clinical data. [5]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength74
4 evidence types, 4 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3 data-appetite signals (3 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ review — This company's core business is healthcare services, but it has a dedicated research division and a startup actively developing and productizing AI/predictive algorithms based on its own patient data, making it a seller of intelligence and thus a bad fit. Issues: Company is actively developing AI software products (NefroCloud, RENALERT-AI) based on its proprietary data. [19, 22, 23]; It has a dedicated health-tech startup for predictive AI algorithms that was selected for a Silicon Valley bootcamp, indicating a clear strategy to productize i; The stated goal of research projects like SIATE is to create 'large-scale, structured databases for Network Medicine and AI applications in both clinical and ma; The company is a large, multi-regional group with over 50 centers, acquiring other hospitals, and is likely too large to be considered an SME. [1, 16]
- Deep Qualification90
✓ pass — Nefrocenter is a primary healthcare provider, and its data is a byproduct of its services. The company's focus on diagnostic imaging and its active, AI-focused research division make its medical imaging and patient data a plausible and valuable asset, though data licensing rights are not explicitly clear and are subject to strict GDPR regulation.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence indicates a collection of patient records from specialized care, providing crucial clinical context for nephrology and diabetic patient cohorts that is essential for training accurate diagnostic models.
IoT / sensor data
The group's use of cutting-edge technologies in specialized care like dialysis suggests the presence of time-series data from connected medical devices, offering a rich source for predictive AI models.
Image collection
Nefrocenter directly confirms its operations in imaging diagnostics across multiple high-value specialties, proving ownership of the core visual data required by diagnostic AI developers.
business_records
The company's formal agreements with the Italian National Health Service for laboratory diagnostics confirm a history of generating structured, high-quality diagnostic data suitable for regulatory-aware AI applications.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Nefrocenter Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics Market = $1.1 Billion in 2023, CAGR 25.2% (source: Market.us). Investment score 47.5/100 (confidence 0.56). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Distalmotion — Medical Imaging Dataset Opportunity
View opportunity →healthcareEndoquestrobotics — Medical Imaging Dataset Opportunity
View opportunity →healthcareMotusnova — Sensor Telemetry Dataset Opportunity
View opportunity →